BioNTech Halts Colorectal Cancer Vaccine Trial Amid Futility Concerns
BioNTech's experimental mRNA cancer vaccine trial has been halted after an independent committee found it unlikely to help patients with colorectal cancer live longer. The trial, which was testing whether the autogene cevumeran vaccine could prevent recurrence in high-risk patients who had undergone surgery and still had traces of cancer DNA in their blood, showed a 'numerical imbalance' in overall survival between the patient groups.
According to analysts, this means more deaths occurred in the vaccine group than the control group. The committee responsible for overseeing the safety and integrity of the trial concluded that continuing it was unlikely to show the vaccine's effectiveness.
The setback comes days after Merck and Moderna announced success with their mRNA-based vaccine in preventing melanoma recurrence. BioNTech's shares had risen 20% on the day, but fell 7.5% after the news of the trial's failure.
Analysts say the failure is a negative signal for mRNA vaccines in 'cold' tumors historically resistant to immunotherapy, like colorectal and pancreatic cancers. The company is shifting its focus towards its non-mRNA pipeline, particularly antibody-drug conjugates (ADCs) and bispecific cancer therapies.